view4D pharma PLC

4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company.

Peyton says the merger will accelerate and de-risk 4D's admission to NASDAQ while providing immediate access to additional funds to support the group's pipeline of therapies. He adds it also will likely increase interest from US healthcare investors provide access to a much larger pool of specialist capital.

Quick facts: 4D pharma PLC

Price: 129.7 GBX

Market: LSE
Market Cap: £1.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...


4d pharma says Merck KGaA and Pfizer cancer collaboration is 'big step forward'

4D pharma PLC's (LON:DDDD) chief executive Duncan Peyton talks to Proactive London's Katie Pilbeam about the clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc. Peyton says 'it's another step forward in how we work and expand our oncology franchise' which will...

2 weeks, 6 days ago

2 min read